Licenses and licensing conditions may vary from country to country. Please always consult your country specific SPC or package leaflet.
In the regular course of business, Baxter interacts and communicates directly with consumers, patients, health-care professionals, employees and others. These audiences may share their personally identifiable information with Baxter which we collect, store and process electronically and/or manually. Please see the following Global Privacy Principles that govern Baxter´s use of personally identifiable information ("Private Information"). Since Baxter has many websites developed by Baxter business units and regions that can be accessed via the www.baxter.com site, please also see the information provided in the section entitled "Baxter´s Website Policies" below.
IMPORTANT: Baxter´s Global Privacy Statement states: "In all instances, Baxter believes that it is a person´s right to have their personal information kept private. Therefore, we have an obligation to implement privacy procedures and technical security measures to keep personal information private and secure." If you should have any questions concerning Baxter´s privacy practices or wish to access or correct Private Information that Baxter has collected from you, please submit an inquiry via Baxters on-line Privacy Inquiry Form, call: 1-800-422-9837 (847-948-4770) or fax your inquiry to 847-948-3642.
Baxter’s BioScience business applies a unique combination of expertise in medical devices, pharmaceuticals, and biotechnology to create products that improve patient care worldwide.
Baxter is investigating uses within its immunoglobulin portfolio in neurology and immunology, for disorders such as Alzheimer’s disease and multifocal motor neuropathy (MMN).
Baxter’s BioScience business, in conjunction with Halozyme Therapeutics, is investigating new delivery technology for subcutaneous administration of IVIg.
Baxter is a fully integrated business that fully complies with regulatory requirements to ensure product safety, efficacy, and quality. This helps assure high quality products from the plasma donors to patients who benefit from our therapies.
The Baxter Global Pathogen Safety Group is an established world leader regarding the safety of plasma-derived therapeutics. The group is dedicated and focused on reducing the risk to Baxter products from current and emerging pathogens.
Baxter has a cutting edge biologics manufacturing expertise in plasma fractionation, recombinant protein production, and proprietary Vero cell vaccine production technology. Baxter’s plasma fractionation facilities strive to increase efficiency and support greater product yields, to ensure that more patients have access to its therapies. The company’s experience in plasma fractionation has also resulted in the development of reliable and innovative therapies for the treatment of various chronic conditions.
Baxter BioScience Grants Program
For more information on subcutaneous injection, please click here to view the video.